Acurx Pharmaceuticals Dirección
Dirección controles de criterios 1/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Dave Luci
Chief Executive Officer (CEO)
US$1.0m
Compensación total
| Porcentaje del salario del CEO | 46.4% |
| Permanencia del CEO | 6.8yrs |
| Participación del CEO | 6.8% |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 3.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Acurx Pharmaceuticals (NASDAQ:ACXP) Will Have To Spend Its Cash Wisely
Aug 11
Acurx Sell-Off Presents Opportunity Before Upcoming Data Release
Jan 22Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
Oct 30Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?
Jul 15Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?
Mar 04Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
Nov 16Acurx, Pharmaceuticals drops 8.8%, announces $4.25M direct offering
Jul 25Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
May 13Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
Jan 22Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth
Sep 30New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers
Aug 27Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$16m |
| Jun 30 2024 | n/a | n/a | -US$17m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$1m | US$475k | -US$15m |
| Sep 30 2023 | n/a | n/a | -US$13m |
| Jun 30 2023 | n/a | n/a | -US$13m |
| Mar 31 2023 | n/a | n/a | -US$12m |
| Dec 31 2022 | US$655k | US$475k | -US$12m |
| Sep 30 2022 | n/a | n/a | -US$11m |
| Jun 30 2022 | n/a | n/a | -US$13m |
| Mar 31 2022 | n/a | n/a | -US$14m |
| Dec 31 2021 | US$4m | US$364k | -US$13m |
| Sep 30 2021 | n/a | n/a | -US$11m |
| Jun 30 2021 | n/a | n/a | -US$8m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | US$596k | US$277k | -US$5m |
| Dec 31 2019 | US$290k | US$267k | -US$6m |
Compensación vs. Mercado: La compensación total de Dave($USD1.02M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD647.72K).
Compensación vs. Ingresos: La compensación de Dave ha aumentado mientras la empresa no es rentable.
CEO
Dave Luci (57 yo)
6.8yrs
Permanencia
US$1,023,878
Compensación
Mr. David P. Luci, also known as Dave, CPA, J.D. Esq. served as Chairman of the Board at AMERI Holdings, Inc. since August 16, 2018 until December 12, 2018.Mr. Luci is the Co-Founder of Acurx Pharmaceutic...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 6.8yrs | US$1.06m | 5.94% $ 1.1m | |
| Co-Founder | 6.8yrs | US$1.02m | 6.76% $ 1.3m | |
| Independent Director | 3.3yrs | US$78.94k | 0.019% $ 3.6k | |
| Independent Director | 3.3yrs | US$73.94k | 0.0095% $ 1.8k | |
| Independent Director | 3.3yrs | US$76.44k | 0.077% $ 14.8k | |
| Independent Director | 6.1yrs | US$66.44k | 0.72% $ 139.4k | |
| Independent Director & Scientific Advisor | 3.3yrs | US$61.44k | 0.11% $ 21.0k | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Scientific Advisor | no data | sin datos | sin datos |
3.3yrs
Permanencia media
71yo
Promedio de edad
Junta con experiencia: La junta directiva de ACXP se considera experimentada (3.3 años de antigüedad promedio).